-
公开(公告)号：WO2002100343A3
公开(公告)日：2002-12-19
申请号：PCT/US2002/018478
申请日：2002-06-10
Applicant: MANDALMED, INC. , JARVIS, Gary, A. , JOHN, Constance, M. , LEFFLER, Hakon
Inventor： JARVIS, Gary, A. , JOHN, Constance, M. , LEFFLER, Hakon
IPC: A61K38/16
Abstract: There is provided a composition having an effective amount of N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier. The present invention also provides an antibody that specifically binds to carbohydrate ligands of galectin-3. Further, there is provided an anti-cancer treatment having an effective amount of N -terminally truncated galectin-3 and a pharmaceutically acceptable carrier or an effective amount of nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
-
Patent Agency Ranking2.发明申请SUSTAINED RELEASE N-TERMINALLY TRUNCATED GALECTIN-3 AND ANTIBIDIES TO GALECTIN-3 CARBOHYDRATE LIGANDS FOR USE IN TREATING CANCER 审中-公开持续释放 N - 细胞截短的GALECTIN-3和用于治疗癌症的GALECTIN-3碳水化合物配体的抗体
公开(公告)号：WO2002100343A2
公开(公告)日：2002-12-19
申请号：PCT/US2002/018478
申请日：2002-06-10
Applicant: MANDALMED, INC. , JARVIS, Gary, A. , JOHN, Constance, M. , LEFFLER, Hakon
Inventor： JARVIS, Gary, A. , JOHN, Constance, M. , LEFFLER, Hakon
IPC: A61K
CPC classification number: A61K38/1709 , A61K9/1647 , A61K47/60 , A61K2039/505 , C07K16/2851
Abstract: There is provided a composition having an effective amount of N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier. The present invention also provides an antibody that specifically binds to carbohydrate ligands of galectin-3. Further, there is provided an anti-cancer treatment having an effective amount of N -terminally truncated galectin-3 and a pharmaceutically acceptable carrier or an effective amount of nucleic acid sequence encoding N -terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
Abstract translation: 提供在药学上可接受的载体中具有有效量的N末端截短的半乳凝素-3的组合物或有效量的编码N末端截短的核酸序列 半乳凝素-3在药学上可接受的载体中。 本发明还提供了一种通过向需要这种治疗的患者施用有效量的在药学上可接受的载体中的N-末端截短的半乳凝素-3或有效量的 在药学上可接受的载体中编码N-末端截短的半乳凝素-3的核酸序列。 本发明还提供了与galectin-3的碳水化合物配体特异性结合的抗体。 此外，提供了具有有效量的N末端截短的半乳凝素-3和药学上可接受的载体或有效量的编码N i的核酸序列的抗癌治疗 > - 最终截短的半乳凝素-3在药学上可接受的载体中。
-
公开(公告)号：WO2005113569A1
公开(公告)日：2005-12-01
申请号：PCT/SE2005/000766
申请日：2005-05-23
Applicant: FORSKAPATENT I SYD AB , NILSSON, Ulf , LEFFLER, Hakon , SALAMEH, Bader, Abdalraheem, Bader
Inventor： LEFFLER, Hakon , SALAMEH, Bader, Abdalraheem, Bader
IPC: C07H19/056
CPC classification number: C07H19/056
Abstract: The present invention relates to novel 3-triazolyl-galactosides, the use of said triazolyl-galactosides as medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. Said galactin is preferably a galactin-3.
Abstract translation: 本发明涉及新的3-三唑基 - 半乳糖苷，所述三唑基 - 半乳糖苷作为药物的用途以及用于制备用于治疗与哺乳动物中的半乳聚糖与受体结合相关的疾病的药物。 所述半乳聚糖优选为半乳聚糖-3。
-
公开(公告)号：WO2005113568A1
公开(公告)日：2005-12-01
申请号：PCT/SE2005/000757
申请日：2005-05-20
Applicant: FORSKARPATENT I SYD AB , NILSSON, Ulf , LEFFLER, Hakon , CUMPSTEY, Ian
Inventor： NILSSON, Ulf , LEFFLER, Hakon , CUMPSTEY, Ian
IPC: C07H13/04
Abstract: The present invention relates to novel galactosides and the use of the galactosides as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to receptors in a mammal. Said galectin is preferably galectin-3.
Abstract translation: 本发明涉及新的半乳糖苷和半乳糖苷作为药物的用途，以及用于制备用于治疗与哺乳动物中的半乳聚糖与受体结合相关的疾病的药物。 所述半乳凝素优选为半乳凝素-3。
-
公开(公告)号：WO02057284A8
公开(公告)日：2004-05-27
申请号：PCT/SE0200089
申请日：2002-01-21
Applicant: NILSSON ULF , LEFFLER HAKON , SOERME PERNILLA
Inventor： NILSSON ULF , LEFFLER HAKON , SOERME PERNILLA
Abstract: The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin 3.
Abstract translation: 本发明涉及新化合物，所述化合物在药物中的用途以及制备用于治疗与半乳凝素与哺乳动物受体结合有关的病症的药物。 所述半乳凝素优选为半乳凝素3。
-
公开(公告)号：WO2010126435A1
公开(公告)日：2010-11-04
申请号：PCT/SE2010/050458
申请日：2010-04-26
Applicant: FORSKARPATENT I SYD AB , LEFFLER, Hakon , NILSSON, Ulf J. , VON WACHENFELDT, Henrik
Inventor： LEFFLER, Hakon , NILSSON, Ulf J. , VON WACHENFELDT, Henrik
IPC: C07H15/22 , A61K31/7028 , A61K31/7056 , A61P19/02 , A61P29/00 , A61P35/00 , C07H19/056 , C07H5/06
CPC classification number: C07H15/207 , C07H15/22 , C07H19/056
Abstract: The present invention relates to novel compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in said galectin is preferably a galectin-3. The novel compounds are defined by the general formula: (I)
Abstract translation: 本发明涉及具有如下效果的新化合物。 半乳凝素抑制剂，所述化合物作为药物的用途以及制备用于治疗与半乳凝素与哺乳动物中的受体结合有关的病症的药物，其中所述半乳凝素优选为半乳凝素-3。 新化合物由以下通式定义：（I）
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
